164 related articles for article (PubMed ID: 38338777)
21. Real-world effectiveness and sensitivity of palbociclib plus endocrine therapy in HR+/HER2- patients with metastatic breast cancer.
Li J; Zhang X; Yang C; Lv Y; Yang H; Kong X; Han M; Wang Z; Ma J; Han J; Liu Y
Medicine (Baltimore); 2021 Nov; 100(44):e27710. PubMed ID: 34871262
[TBL] [Abstract][Full Text] [Related]
22. Palbociclib and beyond for the treatment of HR + HER2- metastatic breast cancer: an Asian-Pacific perspective and practical management guide on the use of CDK4/6 inhibitors.
Dawood S; Chiu JW; Huang CS; Nag S; Sookprasert A; Yap YS; Md Yusof M
Curr Med Res Opin; 2020 Aug; 36(8):1363-1373. PubMed ID: 32544344
[TBL] [Abstract][Full Text] [Related]
23. Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.
Turner NC; Ro J; André F; Loi S; Verma S; Iwata H; Harbeck N; Loibl S; Huang Bartlett C; Zhang K; Giorgetti C; Randolph S; Koehler M; Cristofanilli M;
N Engl J Med; 2015 Jul; 373(3):209-19. PubMed ID: 26030518
[TBL] [Abstract][Full Text] [Related]
24. High-throughput screens identify microRNAs essential for HER2 positive breast cancer cell growth.
Leivonen SK; Sahlberg KK; Mäkelä R; Due EU; Kallioniemi O; Børresen-Dale AL; Perälä M
Mol Oncol; 2014 Feb; 8(1):93-104. PubMed ID: 24148764
[TBL] [Abstract][Full Text] [Related]
25. Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (PALOMA-1, TRIO-18).
Finn RS; Boer K; Bondarenko I; Patel R; Pinter T; Schmidt M; Shparyk YV; Thummala A; Voitko N; Bananis E; McRoy L; Wilner K; Huang X; Kim S; Slamon DJ; Ettl J
Breast Cancer Res Treat; 2020 Sep; 183(2):419-428. PubMed ID: 32683565
[TBL] [Abstract][Full Text] [Related]
26. Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells.
Ogata R; Kishino E; Saitoh W; Koike Y; Kurebayashi J
Breast Cancer; 2021 Jan; 28(1):206-215. PubMed ID: 32860163
[TBL] [Abstract][Full Text] [Related]
27. Exemestane plus everolimus and palbociclib in metastatic breast cancer: clinical response and genomic/transcriptomic determinants of resistance in a phase I/II trial.
Gómez Tejeda Zañudo J; Barroso-Sousa R; Jain E; Jin Q; Li T; Buendia-Buendia JE; Pereslete A; Abravanel DL; Ferreira AR; Wrabel E; Helvie K; Hughes ME; Partridge AH; Overmoyer B; Lin NU; Tayob N; Tolaney SM; Wagle N
Nat Commun; 2024 Mar; 15(1):2446. PubMed ID: 38503755
[TBL] [Abstract][Full Text] [Related]
28. Exploratory analysis of biomarkers associated with clinical outcomes from the study of palbociclib plus endocrine therapy in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer.
Lee S; Park K; Kim GM; Jung KH; Kang SY; Park IH; Kim JH; Ahn HK; Park WY; Im SA; Park YH
Breast; 2022 Apr; 62():52-60. PubMed ID: 35124320
[TBL] [Abstract][Full Text] [Related]
29. CDK4/6 inhibitors for the treatment of advanced hormone receptor positive breast cancer and beyond: 2016 update.
O'Sullivan CC
Expert Opin Pharmacother; 2016 Aug; 17(12):1657-67. PubMed ID: 27322766
[TBL] [Abstract][Full Text] [Related]
30. Cyclin-dependent kinase 4/6 inhibitors for the management of advanced or metastatic breast cancer in women.
Cersosimo RJ
Am J Health Syst Pharm; 2019 Aug; 76(16):1183-1202. PubMed ID: 31369120
[TBL] [Abstract][Full Text] [Related]
31. The effect of low HER2 expression on treatment outcomes in metastatic hormone receptor positive breast cancer patients treated with a combination of a CDK4/6 inhibitor and endocrine therapy: A multicentric retrospective study.
Caliskan Yildirim E; Atag E; Coban E; Umit Unal O; Celebi A; Keser M; Uzun M; Keskinkilic M; Tanrikulu Simsek E; Sari M; Yavuzsen T
Breast; 2023 Aug; 70():56-62. PubMed ID: 37343321
[TBL] [Abstract][Full Text] [Related]
32. Overexpression of TK1 and CDK9 in plasma-derived exosomes is associated with clinical resistance to CDK4/6 inhibitors in metastatic breast cancer patients.
Del Re M; Bertolini I; Crucitta S; Fontanelli L; Rofi E; De Angelis C; Diodati L; Cavallero D; Gianfilippo G; Salvadori B; Fogli S; Falcone A; Scatena C; Naccarato AG; Roncella M; Ghilli M; Morganti R; Fontana A; Danesi R
Breast Cancer Res Treat; 2019 Nov; 178(1):57-62. PubMed ID: 31346846
[TBL] [Abstract][Full Text] [Related]
33. Systemic Therapies Following Progression on First-line CDK4/6-inhibitor Treatment: Analysis of Real-world Data.
Martin JM; Handorf EA; Montero AJ; Goldstein LJ
Oncologist; 2022 Jun; 27(6):441-446. PubMed ID: 35552450
[TBL] [Abstract][Full Text] [Related]
34. Comparative efficacy and safety of CDK4/6 and PI3K/AKT/mTOR inhibitors in women with hormone receptor-positive, HER2-negative metastatic breast cancer: a systematic review and network meta-analysis.
Han Y; Wang J; Wang Z; Xu B
Curr Probl Cancer; 2020 Dec; 44(6):100606. PubMed ID: 32446638
[TBL] [Abstract][Full Text] [Related]
35. Palbociclib: A Review in HR-Positive, HER2-Negative, Advanced or Metastatic Breast Cancer.
Kim ES; Scott LJ
Target Oncol; 2017 Jun; 12(3):373-383. PubMed ID: 28488183
[TBL] [Abstract][Full Text] [Related]
36. Prognostic Parameters of Palbociclib in HR+/HER2- Advanced Breast Cancer: A Narrative Review.
Wang W; Wu J; Chen K; Wang X; Shao X
Technol Cancer Res Treat; 2023; 22():15330338231173504. PubMed ID: 37186799
[TBL] [Abstract][Full Text] [Related]
37. Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER+ Breast Cancers.
Soosainathan A; Iravani M; El-Botty R; Alexander J; Sourd L; Morisset L; Painsec P; Orha R; Nikitorowicz-Buniak J; Pancholi S; Haider S; Dowsett M; Marangoni E; Martin LA; Isacke CM
Cancer Res; 2024 Jan; 84(1):17-25. PubMed ID: 37801608
[TBL] [Abstract][Full Text] [Related]
38. Molecular pathogenesis of breast cancer: impact of miR-99a-5p and miR-99a-3p regulation on oncogenic genes.
Shinden Y; Hirashima T; Nohata N; Toda H; Okada R; Asai S; Tanaka T; Hozaka Y; Ohtsuka T; Kijima Y; Seki N
J Hum Genet; 2021 May; 66(5):519-534. PubMed ID: 33177704
[TBL] [Abstract][Full Text] [Related]
39. Time to treatment failure of palbociclib and letrozole as second-line therapy or beyond in hormone receptor-positive advanced breast cancer.
Schickli MA; Berger MJ; Lustberg M; Palettas M; Vargo CA
J Oncol Pharm Pract; 2019 Sep; 25(6):1374-1380. PubMed ID: 30134767
[TBL] [Abstract][Full Text] [Related]
40. Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor-Positive Metastatic Breast Cancer.
Turner NC; Liu Y; Zhu Z; Loi S; Colleoni M; Loibl S; DeMichele A; Harbeck N; André F; Bayar MA; Michiels S; Zhang Z; Giorgetti C; Arnedos M; Huang Bartlett C; Cristofanilli M
J Clin Oncol; 2019 May; 37(14):1169-1178. PubMed ID: 30807234
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
